Temperature-dependent Specific Transport of Levofloxacin in Human Intestinal Epithelial LS180 Cells by FUKUMORI, Shiro et al.
BIOPHARMACEUTICS & DRUG DISPOSITION
Biopharm. Drug Dispos. 30: 448–456 (2009)
Published online 31 August 2009 in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/bdd.679
Temperature-dependent Specific Transport of Levofloxacin
in Human Intestinal Epithelial LS180 Cells
Shiro Fukumori, Miki Masago, Kazuya Ishida, Yuichiro Kayano, Masato Taguchi and Yukiya Hashimoto
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
ABSTRACT: It was reported previously that specific levofloxacin uptake in Caco-2 cells was
inhibited by nicotine, enalapril, L-carnitine and fexofenadine. The aim of the present study was to
characterize the cellular uptake of levofloxacin using another human intestinal cell line, LS180.
Levofloxacin uptake in LS180 cells was temperature-dependent and optimal at neutral pH, but was
Na1-independent. The rank order of inhibitory effects of the four compounds on [14C] levofloxacin
uptake in LS180 cells was nicotine>enalapril>L-carnitine>fexofenadine, which is consistent with that
in Caco-2 cells. The mRNA levels of OATP1A2, 1B1, 1B3 and 2B1 in LS180 cells were markedly
different from those in Caco-2 cells, and OATP substrates/inhibitors had no systematic effect on the
levofloxacin uptake. The mRNA levels of OCTN1 and 2 in LS180 cells were similar to those in Caco-2
cells. However, the inhibitory effect of nicotine on L-[3H]carnitine uptake was much less potent than
that of unlabeled L-carnitine. These results indicate that the specific uptake system for levofloxacin in
LS180 cells is identical/similar to that in Caco-2 cells, but that OATPs and OCTNs contribute little to
levofloxacin uptake in the human intestinal epithelial cells. Copyrightr 2009 JohnWiley & Sons, Ltd.
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Introduction
Levofloxacin is well absorbed from the intestine,
and the bioavailability following oral administra-
tion is approximately 100% in humans [1]. Since
levofloxacin is a zwitterionic compound, a passive
diffusion mechanism may not explain fully the
high intestinal absorption [1]. Yamaguchi et al.
reported that apical uptake of levofloxacin in
human intestinal epithelial Caco-2 cells was
markedly decreased by lowering the temperature
(41C) and showed concentration-dependent satura-
tion [2]. In order to evaluate the membrane
transport responsible for intestinal absorption of
levofloxacin, pharmacokinetic analysis of the trans-
cellular transport of levofloxacin across Caco-2 cell
monolayers grown on porous membrane filters
was performed previously [3]. The apical influx
clearance value of levofloxacin was greater than the
basolateral influx clearance value in Caco-2 cells [3].
In addition, the apical uptake of [3H]glycylsarcosine
(Gly-Sar) in Caco-2 cells was significantly inhibited
by Ala-Ala, whereas that of [14C]levofloxacin was
not inhibited by Ala-Ala and Gly-Sar [4]. On the
other hand, the apical uptake of [14C]levofloxacin in
Caco-2 cells was significantly inhibited by several
structurally unrelated compounds, such as nicotine,
fexofenadine, enalapril and L-carnitine. These
results suggested that levofloxacin uptake across
the apical membrane in Caco-2 cells was mediated
by a specific transport system other than the
peptide transport system [4]. The primary aim of
the present study was to examine whether the
specific transport system for levofloxacin is present
in another human intestinal epithelial cell line,
LS180, which is a microvillus-expressing cell line
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that possesses characteristics of the small intestine,
and has been used as an in vitro model of the
intestine [5–9]. In addition, the inhibitory effects
of the four compounds (nicotine, fexofenadine,
enalapril and L-carnitine) on the uptake of [14C]-
levofloxacin in LS180 cells were compared with
those in Caco-2 cells.
Nicotine consists of a pyridine and an N-methyl
pyrrolidine ring, thereby being a cyclic tertiary
amine; however, there has been limited informa-
tion about the intestinal transport of nicotine [10].
On the other hand, fexofenadine is a selective
histamine H1 receptor antagonist and a zwitterion
which contains a carboxyl group and a piperidino
group [11]. Organic anion transporting polypep-
tide 1A2 (OATP1A2) mediated fexofenadine up-
take in single-transfected HeLa cells [12]. Enalapril
is an angiotensin-converting enzyme (ACE) in-
hibitor and a modified Ala-Pro, which consists
of a free carboxylic acid moiety and an amide
bond [13]. OATP1B1 and OATP1B3 are involved in
the transport of enalapril in single-transfected
HEK 293 cells, whereas the intestinal peptide
transporter (PEPT1) may contribute little to the
intestinal absorption of enalapril [14,15]. On the
other hand, L-carnitine exists in vivo as a zwitter-
ion, and is a highly hydrosoluble compound with
a quaternary amine and a carboxylic acid moiety
[16]. The uptake of L-carnitine in Caco-2 cells is
primarily mediated by the organic cation trans-
porter novel type 2 (OCTN2), and OCTN1
expressed in the human intestine is also capable
of transporting L-carnitine [16,17]. The secondary
aim of the present study was to investigate the
involvement of OATPs and/or OCTNs in the
specific transport of levofloxacin in LS180 cells.
That is, the effects of OATP substrates/inhibitors
and also carboxylate-type compounds on the
cellular uptake of [14C] levofloxacin were evalu-
ated in LS180 cells. In addition, the uptake
characteristics of L-carnitine in LS180 cells were
compared with those of levofloxacin.
Materials and Methods
Materials
[14C]Levofloxacin (2.43MBq/mg) was kindly
donated by Daiichi Pure Chemicals Co.
(Ibaraki, Japan). L-[N-Methyl-3H]carnitine
hydrochloride (L-[3H]carnitine) (3145GBq/mmol)
and [3H]mannitol (740GBq/mmol) were pur-
chased from American Radiolabeled Chemicals
Inc. (St Louis, MO, USA). [14C]Mannitol
(1.96GBq/mmol) was purchased from Moravek
Biochemicals Inc. (Brea, CA, USA). Levofloxacin
hydrochloride was purchased from LKT Labora-
tories (St Paul, MN, USA). L-Carnitine hydro-
chloride and Dulbecco’s modified Eagle’s medium
(DMEM) were acquired from Nacalai Tesque
(Kyoto, Japan). Fetal bovine serum (FBS) was
acquired from Biowest Inc. (Nuaille, France). All
other chemicals were of the finest grade available.
Cell culture
LS180 cells at passage number 38 were obtained
from the American Type Culture Collection
(Manassas, VA, USA). The cells were maintained
by serial passage in plastic dishes with DMEM
supplemented with 10% heat-inactivated FBS,
100 mM nonessential amino acids, 100 units/ml
penicillin G and 100 mg/ml streptomycin in
an atmosphere of 5% CO2–95% air at 371C [8].
The cell lines were seeded at a density
5 105 cells/cm2 on a 3.8 cm2 plastic dish using
a Falcons multiwellTM plate (BD Bioscience,
Bedford, MA, USA), and maintained for 7 days.
All experiments were conducted with LS180 cells
between passages 54 to 69.
Caco-2 cells at passage number 43 were
obtained from the Riken Bioresource Center
(Tsukuba, Japan). To determine mRNA expres-
sion of transporters in Caco-2 cells, the cells
were maintained for 21 days [6]. All experiments
were conducted with Caco-2 cells between
passages 62 to 66.
Real-time PCR assay of solute carrier transporter
mRNA in Caco-2 and LS180 cells
Total RNA was isolated from Caco-2 and LS180
cells using an RNA extraction kit (RNeasysMini
Kit, Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions [8]. Reverse trans-
cription of extracted total RNAwas performed as
described previously [8]. Real-time PCR was
carried out on an Mx3000Ps QPCR System
(Stratagene, La Jolla, CA, USA) using SYBRs
Premix Ex TaqTM (TaKaRa, Shiga, Japan) according
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to the manufacturer’s instructions. The sequen-
ces of the specific primers have been reported
elsewhere [12,18,19]. Cycling conditions were 1
cycle for 30 s at 951C, followed by 45 cycles of 5 s
denaturation at 951C, 20 s annealing at 601C and
15 s extension at 721C [8]. The mRNA level of
transporters was normalized according to the
GAPDH mRNA level, and the ratio is presented
using a common logarithm.
Uptake of levofloxacin in LS180 cells
The cellular uptake of [14C]levofloxacin was
examined using LS180 cells grown on plastic
dishes of multiwell plates. The composition of
the incubation medium was as follows: 125mM
NaCl, 4.8mM KCl, 5.6mM D-glucose, 1.2mM
CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4  7H2O
and 25mM HEPES (pH 6.0), and the pH of the
medium was adjusted with a solution of NaOH.
The cells were first pre-incubated for 15min at
371C with 2ml incubation medium containing
unlabeled 20 mM levofloxacin to equilibrate the
drug concentration. After the pre-incubation
period, the incubation medium was replaced
with 0.5ml fresh incubation medium containing
[14C]levofloxacin (0.1 mCi/well). After the cells
were incubated with [14C]levofloxacin for an-
other 5–30min at 371C, they were immediately
washed with ice-cold phosphate buffer and
collected. Radioactivities in the cells were deter-
mined using a liquid scintillation counter and
normalized against the initially applied doses. To
estimate the extracellular trapping of the radio-
labeled drug, the amount of [3H]mannitol in the
cells was also determined [4].
In order to evaluate the Na1 dependence of the
cellular uptake of [14C]levofloxacin, incubation
medium containing various Na1 concentrations
was prepared by replacing NaCl with N-methyl-
D-glucamine hydrochloride, and the pH of the
medium was adjusted to 6.0 by the addition of
KOH. When uptake was measured at an acidic or
alkaline pH (pH 5.0–8.0), the pH of the medium
was adjusted using HCl or NaOH.
The effect of various compounds on the uptake
of [14C]levofloxacin in LS180 cells on plastic
dishes of a multiwell plate was evaluated at
371C in the presence of unlabeled 10–100 mM
levofloxacin. The cells were first pre-incubated
for 15min at 371C with 2ml incubation medium.
The incubation medium was replaced with 450 ml
fresh incubation medium supplemented with
various compounds at 5min before the addition
of 50 ml solution of [14C]levofloxacin (0.1 mCi/
well). After the cells were incubated with
[14C]levofloxacin for 15min at 371C, the amount
of [14C]levofloxacin in the cells was determined
as described above.
Uptake of L-carnitine in LS180 cells
In order to evaluate the cellular uptake of
L-[3H]carnitine in LS180 cells, the cells were first
pre-incubated for 15min at 371C with 2ml
incubation medium containing unlabeled 1 mM
L-carnitine. The incubation medium was
replaced with 0.5ml fresh incubation medium
containing L-[3H]carnitine (0.1 mCi/well). After
the cells were incubated with L-[3H]carnitine
for another 15min at 371C, the amount of
L-[3H]carnitine in the cells was determined as
described above. To estimate the extracellular
trapping of the radio-labeled drug, the amount of
[14C]mannitol in the cells was also determined.
In order to evaluate the Na1 dependence of the
cellular uptake of L-[3H]carnitine, incubation
medium containing various Na1 concentrations
was prepared by replacing NaCl with N-methyl-
D-glucamine hydrochloride, and the pH of the
medium was adjusted to 6.0 by the addition of
KOH. When uptake was measured at an acidic or
alkaline pH (pH 5.0–8.0), the pH of the medium
was adjusted using HCl or NaOH.
The effect of various compounds on the uptake
of L-[3H]carnitine in LS180 cells was evaluated at
371C in the presence of unlabeled 1–10 mM
L-carnitine. The incubation medium was re-
placed with 450 ml fresh incubation medium
supplemented with various compounds at
5min before the addition of the 50 ml solution of
L-[3H]carnitine (0.1 mCi/well). After the cells
were incubated with L-[3H]carnitine for 15min
at 371C, the amount of L-[3H]carnitine in the cells
was determined as described above.
Statistical analysis
Values are expressed as the mean7SE. In all
figures, when error bars are not shown, they are
smaller than the symbol. Multiple comparisons
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were performed using Scheffe´’s test following
one-way ANOVA provided that the variances
of groups were similar. If this was not the case,
the Scheffe´-type test was applied following
Kruskal-Wallis analysis. A value of po0.05 was
considered to be statistically significant.
Results
Expression of OATPs and OCTNs mRNA in
Caco-2 and LS180 cells
The mRNA levels of OATPs and OCTNs in LS180
cells were compared with those in Caco-2 cells by
real-time PCR (Figure 1). In addition, the mRNA
expression of PEPT1 was measured for reference,
because the specific transport of Gly-Sar was
observed in Caco-2 cells [4]. The expression of
PEPT1 mRNA in LS180 cells was much lower
than that in Caco-2 cells, and the expression
pattern of OATP mRNAs in LS180 cells was
markedly different from that in Caco-2 cells
(Figure 1). That is, the expression of OATP1A2
mRNA in LS180 cells was much lower than that
in Caco-2 cells, and OATP1B1 was not signifi-
cantly expressed in the two cell lines. The
expression of OATP1B3 mRNA in LS180 cells
was higher than that in Caco-2 cells, whereas the
expression of OATP2B1 mRNA in LS180 cells
was lower than that in Caco-2 cells. On the other
hand, the mRNA for OCTN1 and 2 was
moderately expressed in both Caco-2 and LS180
cells, and the OCTN1/2 mRNA expression ratio
in LS180 cells was similar to that in Caco-2 cells
(Figure 1).
Characterization of levofloxacin uptake in LS180
cells
To investigate the existence of a specific transport
system for levofloxacin in LS180 cells, the time-
dependent uptake of [14C]levofloxacin in LS180
cells was measured. The uptake of [14C]levoflox-
acin at medium pH 6.0 and 371C was 1.19%,
1.51% and 1.68% of the applied dose (20 mM) at 5,
15 and 30min, respectively, which suggested that
the uptake had almost reached a steady state at
15min after the start of incubation. Then the
effects of extracellular Na1 and pH on the 15min
uptake of [14C]levofloxacin were examined in
LS180 cells (Figure 2). The uptake of [14C]levo-
floxacin at 371C was not Na1-dependent in the
concentration range of 25–125mM. On the other
hand, [14C]levofloxacin uptake in LS180 cells was
1.3-fold higher at physiological pH 7.4 than at
acidic pH 5.0 (po0.05). In addition, the cellular
uptake was markedly decreased at 41C (Figure 2).
These results indicated that the uptake of
levofloxacin in LS180 cells was mediated by
Figure 1. Relative mRNA expression of several SLC trans-
porters in Caco-2 (open columns) and LS180 (closed columns)
cells. Each column represents the mean7SE for three
measurements
Figure 2. Na1 (A) and pH (B) dependence of cellular uptake of
levofloxacin in LS180 cells. Cells were incubated with
[14C]levofloxacin for 15min at 371C (open circles) or 41C
(closed circles) in the presence of 20mM unlabeled levofloxacin.
Each point represents the mean7SE for 4–14 measurements.
po0.05: significantly different from pH 7.4 at 371C
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a temperature-dependent specific transport
system.
The inhibitory effects of nicotine, enalapril,
L-carnitine, fexofenadine, and also fluoroquino-
lones, on the uptake of [14C]levofloxacin were
evaluated in LS180 cells (Figure 3). Fexofenadine,
unlabeled levofloxacin and lomefloxacin dec-
reased the uptake of [14C]levofloxacin to 63%,
44% and 37% of the control value, respectively.
L-Carnitine, enalapril and nicotine significantly
decreased the uptake of [14C]levofloxacin to 25%,
19% and 17% of the control value, respectively
(Figure 3). The rank order of inhibitory effects
of the four compounds (nicotine>enalapril>
L-carnitine>fexofenadine) in LS180 cells was
consistent with that in Caco-2 cells [4], which
indicated that the specific transport system
responsible for the levofloxacin uptake in LS180
cells is identical or similar to that in Caco-2 cells.
Inhibitory effect of various OATP substrates/
inhibitors on levofloxacin uptake in LS180 cells
To evaluate the involvement of OATPs in the
levofloxacin uptake in LS180 cells, the effects of
various OATP inhibitors and also carboxylate-
type compounds on the cellular uptake of [14C]-
levofloxacin were further examined. An inhibitor
of OATP1B1 and 1B3, rifampicin, decreased the
uptake of [14C]levofloxacin to 76% of the control
value, whereas other inhibitors of OATP1B1 and
1B3 (bosentan and taurocholic acid) did not
inhibit the uptake of [14C]levofloxacin (Figure 4).
OATP2B1 inhibitors (probenecid and DIDS
(4,40-diisothiocyanatostilbene-2,20-disulfonic acid
disodium salt)) and OATP1A2 inhibitors (hesper-
idin and naringin) had no significant effect on the
uptake of [14C]levofloxacin. A carboxylate-type
compound, methotrexate, decreased the uptake
of [14C]levofloxacin to 62% of the control value,
whereas other carboxylate-type compounds
(folic acid and sulfasalazine) did not inhibit the
uptake of [14C]levofloxacin (Figure 4). These
results indicated that OATPs did not contribute
significantly to the uptake of levofloxacin in
LS180 cells.
Comparison of cellular uptake of L-carnitine and
levofloxacin in LS180 cells
To evaluate whether levofloxacin uptake in LS180
cells is mediated by OCTNs, the uptake profile of
Figure 3. Inhibitory effect of various compounds on cellular
uptake of levofloxacin in LS cells. Cells were incubated
with [14C]levofloxacin for 15min in the presence of 100mM
unlabeled levofloxacin and various compounds. Closed
column represents the mean7SE for 15 measurements, and
open columns represent the mean7SE for 6–8 measurements.
po0.05: significantly different from the control
Figure 4. Inhibitory effect of various compounds, including
OATP inhibitors, on cellular uptake of levofloxacin in LS180
cells. Cells were incubated with [14C]levofloxacin for 15min in
the presence of 100mM unlabeled levofloxacin and various
compounds. Closed column represents the mean7SE for 15
measurements, and open columns represent the mean7SE for
6–8 measurements. po0.05: significantly different from the
control
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L-carnitine in LS180 cells was compared with
that of levofloxacin. The change in extracellular
Na1 concentration between 25 and 125mM had
no significant effect on the uptake of L-[3H]car-
nitine in LS180 cells at 371C (Figure 5A). Raising
the pH of the medium from 5.0 to 8.0 increased
the uptake of L-[3H]carnitine at 371C (Figure 5B).
On the other hand, the uptake of L-[3H]carnitine
at 41C was very low (Figure 5). Next, the study
evaluated the inhibitory effects of various com-
pounds, which inhibited the levofloxacin uptake,
on the uptake of L-[3H]carnitine in LS180 cells.
Since the uptake of L-[3H]carnitine in LS180 cells
was almost completely inhibited by 1mM fexofe-
nadine (data not shown), the inhibitory effects of
the compounds were tested at a concentration of
100 mM (Figure 6). Fexofenadine, levofloxacin and
unlabeled L-carnitine decreased significantly the
uptake of L-[3H]carnitine to 77, 34, and 8% of the
control value, respectively; however, lome-
floxacin, enalapril and nicotine had little effect
on the uptake of L-[3H]carnitine (Figure 6). In
addition, choline chloride, which is structurally
related to L-carnitine, decreased L-[3H]carnitine
uptake to 78% and 24% of the control value
at 5 and 50mM, respectively (Figure 7A). How-
ever, the uptake of [14C]levofloxacin was only
slightly decreased to 91% of the control value
even in the presence of 50mM choline chloride
(Figure 7B). These findings suggested that
OCTNs contributed little to the levofloxacin
uptake in LS180 cells.
Inhibitory effect of angiotensin-converting
enzyme inhibitors on levofloxacin uptake in
LS180 cells
Enalapril significantly inhibited the uptake of
levofloxacin in LS180 cells (Figure 3). In order to
evaluate the substrate recognition characteristics
of the transporter for levofloxacin, the study
further evaluated the effect of several ACE
inhibitors (1mM) on the uptake of [14C]levoflox-
acin in LS180 cells (Figure 8). Perindopril
and lisinopril had no significant effect on the
uptake of [14C]levofloxacin in LS180 cells. On the
other hand, temocapril, quinapril, captopril and
enalapril decreased the uptake of [14C]levoflox-
acin to 59%, 54%, 51% and 50% of the control
value, respectively (Figure 8).
Discussion
Maeda et al. evaluated the levofloxacin uptake
activity of Caco-2 subclones, and selected candi-
date transporter genes functioning for influx
transport of levofloxacin [1]. Based on functional
Figure 5. Na1 (A) and pH (B) dependence of cellular uptake
of L-[3H]carnitine in LS180 cells. Cells were incubated with
L-[3H]carnitine for 15min at 371C (open circles) or 41C (closed
circles) in the presence of 1mM unlabeled L-carnitine. Each
point represents the mean7SE for 6–8 measurements.
po0.05: significantly different from pH 7.4 at 371C
Figure 6. Inhibitory effect of various compounds on cellular
uptake of L-carnitine in LS180 cells. Cells were incubated with
L-[3H]carnitine for 15min in the presence of 1mM unlabeled
L-carnitine and 100mM various compounds. Closed column
represents the mean7SE for 12 measurements, and open
columns represent the mean7SE for 5–6 measurements.
po0.05: significantly different from the control
LEVOFLOXACIN UPTAKE IN LS180 CELLS 453
Copyright r 2009 John Wiley & Sons, Ltd. Biopharm. Drug Dispos. 30: 448–456 (2009)
DOI: 10.1002/bdd
analysis of each transporter gene for which a
good correlation was found between the mRNA
expression level and levofloxacin transport
activity in Caco-2 subclones, OATP1A2 was
concluded to transport levofloxacin. When OAT-
P1A2 was expressed in Xenopus oocytes, levo-
floxacin uptake was essentially pH-independent.
OATP1A2-mediated uptake of levofloxacin
showed a Km value of 136 mM [1]. On the other
hand, the apparent uptake of levofloxacin by
Caco-2 cells showed high- and low-affinity
components with Km values of 0.489 and
14.6mM, respectively. Accordingly, plural trans-
porters are functional for the transport of levo-
floxacin in Caco-2 cells, and OATP1A2 is likely to
function as a high-affinity transporter [1]. How-
ever, it is still unclear which transporter is
responsible for the lower-affinity (high-capacity)
uptake of levofloxacin in Caco-2 cells.
In the present study, the cellular uptake of
levofloxacin was characterized in LS180 cells.
Levofloxacin uptake in LS180 cells was tempera-
ture-dependent and optimal at neutral pH, but
was Na1-independent (Figure 2). The rank order
of the inhibitory effects of the four compounds on
levofloxacin uptake in LS180 cells was nicoti-
ne>enalapril>L-carnitine>fexofenadine (Figure 3),
which is consistent with that in Caco-2 cells [4].
The findings indicated that the specific transport
system responsible for the levofloxacin uptake in
LS180 cells was identical or similar to that in
Caco-2 cells. The expression level of OATP1A2
mRNA in LS180 cells was much lower than that
in Caco-2 cells (Figure 1). In addition, OATP1A2
inhibitors (hesperidin and naringin) did not
inhibit the uptake of levofloxacin in LS180 cells
(Figure 4). The results also suggested that the
uptake of levofloxacin in LS180 cells as well as
Caco-2 cells is mainly mediated by a specific
transport system other than OATP1A2.
OATP1B1, 1B3 and 2B1 are also expressed in
the human intestine [12]. The study further
examined whether these OATPs were involved
in the specific transport of levofloxacin in LS180
cells. The mRNA levels of OATP1B1, 1B3 and 2B1
in LS180 cells were markedly different from those
in Caco-2 cells (Figure 1), and OATP substrates/
inhibitors had no systematic inhibitory effect
on the uptake of levofloxacin in LS180 cells
(Figure 4). In addition, Yamaguchi et al. exam-
ined the effect of organic anions on the uptake of
levofloxacin in Caco-2 cells, and demonstrated
Figure 7. Inhibitory effect of choline chloride on cellular
uptake of L-carnitine and levofloxacin in LS180 cells. (A) Cells
were incubated with L-[3H]carnitine for 15min in the presence
of 10mM unlabeled L-carnitine and choline chloride. (B) Cells
were incubated with [14C]levofloxacin for 15min in the
presence of 10mM unlabeled levofloxacin and choline chloride.
Each column represents the mean7SE for six measurements.
po0.05: significantly different from the control
Figure 8. Inhibitory effect of ACE inhibitors on cellular
uptake of levofloxacin in LS180 cells. Cells were incubated
with [14C]levofloxacin for 15min in the presence of 100mM
unlabeled levofloxacin and 1mM ACE inhibitors. Closed
column represents the mean7SE for 10 measurements, and
open columns represent the mean7SE for 5–7 measurements.
po0.05: significantly different from the control
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that probenecid and DIDS did not inhibit the
uptake of levofloxacin in the cells [2]. These
findings suggested that levofloxacin uptake in
intestinal epithelial cells is mediated by a specific
transport system distinct from OATP1B1, 1B3
and 2B1.
OCTN2 is a physiologically important carni-
tine transporter, and is expressed in the human
intestine [16]. Hirano et al. investigated the
inhibitory effect of levofloxacin on the uptake of
L-carnitine in Caco-2 cells, and showed that
levofloxacin inhibited the apical uptake of
L-carnitine in a non-competitive manner [20]. In
the present study, it was found that the char-
acteristics of levofloxacin uptake in LS180 cells
were different from those of L-carnitine. That is,
nicotine and enalapril inhibited the levofloxacin
uptake significantly (Figure 3); however, the
inhibitory effect of nicotine on L-[3H]carnitine
uptake was much less potent than that of
unlabeled L-carnitine (Figure 6). Furthermore,
choline chloride inhibited the uptake of L-
carnitine, but not of levofloxacin (Figure 7).
These findings suggested that the uptake trans-
porter of levofloxacin is distinct from that of L-
carnitine in intestinal epithelial cells.
Many ACE inhibitors are well absorbed from
the intestine despite their low lipophilicities, and
display absorption rates of 30% to 100% of a dose
[15,21]. However, it is unclear which transporter
is involved in the intestinal absorption of ACE
inhibitors [15]. The present study additionally
examined the effect of several ACE inhibitors on
levofloxacin uptake in LS180 cells (Figure 8). In
addition to enalapril, temocapril, quinapril and
captopril inhibited the uptake of levofloxacin in
LS180 cells (Figure 8). To our knowledge, this is
the first report demonstrating that the uptake of
levofloxacin is affected by several ACE inhibitors
in the intestinal epithelial cells. Further systema-
tic studies will be needed to clarify whether
levofloxacin was transported by the influx
transporter responsible for the intestinal absorp-
tion of ACE inhibitors.
In conclusion, the present results indicated that
the specific transport system responsible for the
levofloxacin uptake in LS180 cells is identical or
similar to that in Caco-2 cells, but that OATPs and
OCTNs contributed little to the uptake of levo-
floxacin in the human intestinal epithelial cells.
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